Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy

BACKGROUND: Thyroid cancer becomes the most common endocrine cancer with the greatest growing incidence in this decade. Sorafenib is a multikinase inhibitor for the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer (DTC), while the off-target toxicity effect is usu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, You, Xiang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289230/
https://www.ncbi.nlm.nih.gov/pubmed/30584304
http://dx.doi.org/10.2147/IJN.S187240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289230/
https://www.ncbi.nlm.nih.gov/pubmed/30584304
http://dx.doi.org/10.2147/IJN.S187240

Ejemplares similares